BCKR, BEDA, CBIS, HTDS, JAZZ, EXPH Stocks to Watch for Tuesday, July 28th from OTCPicks.com
Our Stocks to Watch tomorrow include Blackrock Resources Inc. (OTCBB: BCKR), Bederra Corp. (OTC: BEDA), Cannabis Science Inc. (OTCBB: CBIS), Hard to Treat Diseases Inc. (OTC: HTDS), Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) and Expo Holdings Inc. (OTC: EXPH).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
BLACKROCK RESOURCES INCORPORATED (OTCBB: BCKR)
"Up 263.64% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/BCKR.php
Blackrock Resources Inc. is an independent mineral exploration company engaged in the acquisition, exploration and development of high-quality gold, silver, and copper properties in North and
BCKR News:
July 27 - Blackrock Resources Enters into Letter of Agreement for Joint Venture in
Blackrock Resources Inc. (OTCBB: BCKR) announced that it has signed a letter of agreement with Global Minerals Ltd., a British Columbia company, to enter into a joint venture to develop and exploit Global Minerals' Front Range gold mining project located in the Gold Hill Mining District, Boulder County, Colorado.
Under the terms of the agreement, Blackrock will pay $100,000 to Global Minerals upon signing of a formal joint venture agreement on or before September 15, 2009. The joint venture will be owned 50% by Blackrock and 50% by Global Minerals. To date, Global Minerals has spent approximately $8,000,000 on developing this mining project.
The property has a mill on site that has historically processed 50 tons of ore per day. Through the means of the joint venture, Blackrock intends to increase the mill capacity to between 100 to 200 tons of ore per day, which would produce between 100 to 200 ounces of gold or gold equivalent per day, based upon previous production records. Blackrock believes it can produce these results by increasing the mining capacity within the known vein systems.
Global Minerals has indicated that the project has enough initial reserves to develop the mining capacity to feed a mill of between 100 to 200 tons per day of ore. Further details will be forthcoming as Blackrock's management and consultants review all available information available on the property.
BEDERRA CORPORATION (OTC: BEDA)
"Up 240.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/BEDA.php
Bederra Corporation, through its wholly owned subsidiaries Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater
BEDA News:
July 14 - Bederra Corporation Signs Letter of Intent to Acquire Neogenex Medical Technologies, Inc.
Bederra Corporation (OTC: BEDA), a medical imaging and diagnostic Company, has signed a Letter of Intent to acquire Neogenex Medical Technologies, a Houston, TX based Technology, Development and Marketing company that focuses on Pain Therapies for Arthritis, Soft tissue and Joint applications.
Neogenex Medical Technologies, Inc. has rights to patents and technology to produce and market a low level laser device cleared by the FDA to treat arthritis pain and carpal tunnel syndrome. The company currently markets these FDA approved devices to medical professionals, Fitness Clubs and Corporate Wellness Facilities. More than 3500 medical professionals, therapists and trainers are currently using these devices as treatment options.
"The current market for these products and treatments is well over $10-15 Billion as more than 80 million people can utilize these therapies. Neogenex has already established itself in this market and would make a great addition to Bederra's growing line of products and services," stated Graham Williams, CEO of Bederra.
CANNABIS SCIENCE INCORPORATED (OTCBB: CBIS)
"Up 137.75% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/CBIS.php
Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
CBIS News:
July 27 - Cannabis Science to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medicines in Treatment of H1N1 Swine Flu as AP Report Predicts Swine Flu Could Hit up to 40 Percent in the USA
Cannabis Science, Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to report that it is moving as fast as possible to assist in the fight against the threat of a deadly influenza pandemic. In conjunction with its recent re-organization, the Company has begun discussions with the FDA as its program moves forward to provide FDA approved solutions for several critical illnesses.
H1N1 Swine Flu
According to the CDC, the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.
Cannabis Science H1N1 Swine Flu Formulation
We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its cannabis extract lozenge with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.
Dr. Robert Melamede, Ph.D., Cannabis Science, Inc., President and CEO, believes there is enormous potential value for cannabinoids to naturally reduce excessive inflammatory immune responses, and the Cannabis Science lozenge formulation could reduce the mortality rate and allow infected individuals to develop a strong natural immunity upon recovery. Dr. Melamede is the former Chairman (ret) of the Biology Department at the
Dr. Melamede added, "Again, we recommend, based on sound scientific principles, that medical marijuana users should switch to edibles if they come down with an influenza infection. We believe that the irritation associated with the pulmonary route, when a person has an influenza infection, may lead to unnecessary deaths. In contrast, oral administration may prevent many deaths. We hope that due to the magnitude of this pandemic threat, that the FDA will fast track our proposal."
FDA's three rapid special drug release programs:
Fast Track, Accelerated Approval and Priority Review are approaches that are intended to make therapeutically important drugs available at an earlier time. They do not compromise the standards for the safety and effectiveness of the drugs that become available through this process. These revitalized FDA drug review approaches have yielded tangible results in bringing safe and effective drugs to patients with serious diseases more quickly. For example, since 1996, 68 drugs for cancer therapies have received priority review and approval. The FDA reviewed Gleevec, a treatment for chronic myeloid leukemia, in four months. Shortened review times have also brought promising treatments to patients with HIV/AIDS more quickly. Kaletra for the treatment of HIV/AIDS was reviewed and approved in 3.5 months. Pegasys, a combination product for the treatment of Hepatitis C, was approved for marketing in 4 months.
Fast Track, Accelerated Approval, and Priority Review have evolved over time. The FDA has been vigilant in assuring that reducing the time necessary for drug development has not compromised the safety and effectiveness of drugs for patients with serious diseases. The median time required to review a priority review drug was reduced from 13.9 months to 6.7 months.
HARD TO TREAT DISEASES INCORPORATED (OTC: HTDS)
"Up 127.27% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/HTDS.php
In June 2003, International Foam Solutions, Inc. changed its name to Hard to Treat Diseases, Inc. in connection with the completion of a share exchange agreement with Hard to Treat Diseases and T-19, Inc. Hard to Treat Diseases, Inc. holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating cancer and rheumatoid arthritis under medical patent. Tubercin promotes good health by enhancing the immune system. The nasal spray would be distributed through major holistic retailers and providers worldwide.
HTDS News:
July 23 - Hard to Treat Diseases, Inc. Reports on Ribavirin Research as Potential Treatment for MS
Hard to Treat Diseases, Inc. (OTC: HTDS) reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sclerosis (MS).
The research team has been conducting experiments using Dark Agouti rats. Experimental autoimmune encephalomyelitis (EAE) induced in susceptible strains of animals provides the best available model for studying events in MS and a helpful tool in preclinical testing of various substances considered for treatment of the central nervous system (CNS) disease. CNS is the part of the nervous system that functions to coordinate the activity of all parts of the bodies of multicellular organisms.
In summary, these findings suggest that Ribavirin attenuates experimental autoimmune encephalomyelitis (animal model of multiple sclerosis) by limiting cytokine-mediated immuno-inflammatory events that lead to CNS destruction.
The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.
Dr.Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem said "We are proud to be part of the Hard to Treat Diseases and we are grateful for the funding our division has received. This is of great assistance for continuing of our experiments. We have already ordered some chemicals and antibodies with the funding received. This has afforded us an opportunity to straighten our equipment and to introduce a new methodological approaches and techniques (like PCR and RT-PCR) that would give added value to our research".
Mr. Terry Yuan CEO said, "There is great synergy between the two companies Slavica BioChem and Mellow Hope. Although Slavica currently has no revenues, their developmental and research contributions have the potential to transform into enormous and massive gains for HTDS and its shareholders. We expect to be releasing HTDS Q2 financials shortly, and some positive updates on the IP issue very shortly.
JAZZ PHARMACEUTICALS INCORPORATED (NASDAQ: JAZZ)
"Up 43.84% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/JAZZ.php
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry.
JAZZ News:
July 14 - Beacon Equity Issues Trading Outlook for Jazz Pharmaceuticals Inc.
BeaconEquity.com announces an investment report featuring pharmaceutical company Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ). The report includes a financial and investment analysis, comparative analysis, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Jazz Pharmaceuticals Inc. should be of particular interest to other drug manufacturers: Cephalon Inc. (Nasdaq: CEPH), Sepracor Inc. (Nasdaq: SEPR), Noven Pharmaceuticals Inc. (Nasdaq: NOVN) and Eli Lilly & Co. (NYSE: LLY).
It is available at www.beaconequity.com/i/JAZZ.
EXPO HOLDINGS INCORPORATED (OTC: EXPH)
"Up 45.52% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/EXPH.php
Expo Holdings operates in
EXPH News:
July 27 - Expo Holdings Inc. Announces Shareholder Conference Call
Expo Holdings, Inc. (OTC: EXPH) announces shareholder conference call.
The company will be conducting a shareholder conference call on July 28th, 2009 at 10:00 am ET. Shareholders are invited to attend in person, or call in via:
1-800-615-2900 code #17268.
James D. Brown, CEO, stated, "The Company is pleased to conduct a conference call with its shareholders. We have entered a period of increased business opportunities and significant events have occurred since our last conference call. The company will provide additional sales guidance, updates on current projects, and of course answer any shareholder questions. Due to the number of anticipated participants, each shareholder is limited to one question. You may also email any questions to sales@dddisplays.com and we will try and address them during the introduction."
The company will also make statements regarding our new proprietary product, its introduction to retail, as well as its long term value to the company.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.
